The Board of Directors of Sandoz announced that it proposes Mathai Mammen, M.D., Ph.D., and Michael Rechsteiner for election to its Board of Directors at the company’s Annual General Meeting on April 30, 2024.
Sandoz announces nominations to the Board of Directors and leadership change Read More »
CARBIOS announced that CARBIOS Active, its enzymatic solution for the biodegradation of PLA, is included in the U.S. Food and Drug Administration Inventory of Effective Food Contact Substances with the Assigned Food Contact Notification 2325, effective since 29 February 2024.
Nicox SA, an international ophthalmology company, provided details of poster presentations highlighting data on NCX 470 at the 2024 American Glaucoma Society Annual Meeting, one of the key scientific events in vision research, which was held on February 29th to March 3rd, 2024 in Huntington Beach, CA, United States.
AnHeart Therapeutics and Innovent Biologics, Inc. announced that the Center for Drug Evaluation of China’s National Medical Products Administration has accepted a second New Drug Application for taletrectinib, a next-generation ROS1 tyrosine kinase inhibitor.
Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, confirms that the first patient has been enrolled and treated in its Phase 2 clinical trial of CYP-001 in high-risk acute graft versus host disease.
MaaT Pharma informs on the completion of patient recruitment for the Phase 2a clinical trial1 sponsored by AP-HP2 and in collaboration with INRAE and Institut Gustave Roussy, evaluating MaaT013, the Company’s lead product candidate, in combination with immune checkpoint inhibitors, ipilimumab and nivolumab.
Dentro del fascinante mundo de la física cuántica, el teorema de la no comunicación de la información emerge como un pilar fundamental que desafía nuestras concepciones clásicas de la información y la comunicación. Este teorema, que establece l …
El teorema de la no comunicación de la información Read More »
Innovent Biologics, Inc. and AnHeart Therapeutics announce that the Center for Drug Evaluation of China’s National Medical Products Administration has accepted a second New Drug Application for taletrectinib adipate capsule, a next-generation ROS1 tyrosine kinase inhibitor.
El objetivo de este artículo es describir un enfoque para la evaluación y el tratamiento de las presentaciones comunes del dolor agudo de la columna cervical.
Una consulta común en atención primaria | Dolor cervical agudo Read More »
Las intervenciones para la hiperplasia prostática benigna han evolucionado desde la resección transuretral de la próstata y la prostatectomía simple hasta una infinidad de procedimientos en el consultorio y en el quirófano.
Intervenciones quirúrgicas y procedimientos actuales | Hipertrofia prostática benigna Read More »
